Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With MET Overexpression as a Second-line Treatment
Phase of Trial: Phase II
Latest Information Update: 02 Mar 2017
At a glance
- Drugs Savolitinib (Primary) ; Docetaxel
- Indications Gastric cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 19 Feb 2017 Planned initiation date changed from 1 Sep 2015 to 1 Mar 2017.
- 01 Aug 2016 According to Chi-Med and AstraZeneca media release, first patient dosed in Q3 2015 with estimated completion date as Q1 2018.